Do GLP-1 drugs affect mood, anxiety, or cause suicidal thoughts?

The short answer

GLP-1 drugs like semaglutide and tirzepatide were investigated over reports of suicidal thoughts — but the systematic evidence is reassuring: the FDA reviewed the data, found no increased risk, and requested that the suicidal-ideation warning be removed from the labels, and European regulators found no causal link. One large study even found semaglutide associated with a lower risk of suicidal ideation. Mood and anxiety changes are reported by some, though, and worth monitoring.

Evidence tier: Tier 1 for the regulatory reviews and large studies on suicidality; Tier 2–3 for individual mood/anxiety reports. Educational content, not medical advice.

The key points:

• No evidence GLP-1s cause suicidal thoughts — FDA removed the warning; EMA found no causal link
• *One large study found lower suicidal-ideation risk* on semaglutide
• Mood and anxiety changes happen for some people — often tied to the eating/food relationship shift
• Monitor your mental health and seek help for new or worsening symptoms

For the broader side-effect picture, see managing GLP-1 side effects.

Do GLP-1 drugs cause suicidal thoughts?

Evidence tier: 1 — regulatory reviews and large studies.

This was the most serious concern raised, and it's the one where the evidence is now clearest — and reassuring. After early reports of suicidal thoughts in some people taking GLP-1 drugs, regulators investigated thoroughly. The FDA conducted a comprehensive review of clinical-trial and post-marketing data and found no increased risk of suicidal ideation or behavior, and subsequently requested that manufacturers remove the suicidal-ideation-and-behavior warning from the labels of GLP-1 medications (including Wegovy and Zepbound) (FDA drug safety communication). Europe's regulator reached the same conclusion: the EMA's safety committee reviewed the evidence and found no causal relationship between GLP-1 receptor agonists and suicidal thoughts or self-harm (EMA PRAC).

Beyond the regulators, a large real-world study went further: analyzing hundreds of thousands of patients, it found that semaglutide was associated with a lower — not higher — risk of first-time suicidal ideation compared with other medications used for obesity or type 2 diabetes (Wang et al. 2024, *Nat Med*). So the honest summary is that the headline fear did not hold up under systematic scrutiny: individual case reports prompted a real investigation, and that investigation found no evidence the drugs cause suicidal thoughts, with some evidence pointing the other way. That's an important correction to a scary narrative.

What about depression and low mood?

Evidence tier: 2–3 — mixed, mostly anecdotal.

Depression and low mood are a subtler question, and here the picture is genuinely mixed rather than clearly reassuring or alarming. There is no strong evidence that GLP-1 drugs cause clinical depression, and the same large-scale data that eased the suicidality concern doesn't show these drugs driving depression. But individual experiences vary a lot: some people report low mood or emotional flatness, while many others report improved mood — often attributed to the weight loss itself, better metabolic health, or the relief of quieting constant "food noise."

A plausible piece of the low-mood reports is psychological rather than pharmacological. For people who used food as comfort, reward, or coping, dramatically reducing appetite and eating can remove a source of emotional regulation, which can feel destabilizing even when the weight loss is wanted. That's not the drug "causing depression" so much as a real adjustment to a changed relationship with eating. The practical implication: if you have a history of depression, it's worth discussing with your prescriber before starting and keeping an eye on your mood — not because the drug is likely to cause depression, but because your mental health deserves monitoring during any big change, and support is available if low mood appears.

Can GLP-1 drugs cause anxiety?

Evidence tier: 2–3 — reported, mechanism plausible but unproven.

Anxiety, including "health anxiety," comes up in community discussions — people describing feeling on-edge, or becoming hyper-focused on bodily symptoms after starting. There are a few plausible threads here, none of them proven as a direct drug effect. Gastrointestinal side effects (nausea, reflux, changed digestion) can be uncomfortable and, for someone prone to health anxiety, can trigger worry about what the symptoms mean — a feedback loop where GI discomfort feeds anxious monitoring of the body. Rapid physical change and reading alarming things online can also amplify health anxiety independent of any pharmacological effect.

It's also worth naming that some anxiety around these drugs is situational: waiting on gray-market deliveries, uncertainty about a compound's authenticity, or dosing worries generate real stress that gets attributed to the drug. None of this means GLP-1 drugs "cause anxiety" as a pharmacological fact — the evidence doesn't establish that — but it does mean anxiety experiences are real and worth addressing. If GI symptoms are driving the worry, managing those (covered in managing GLP-1 side effects) often helps; if the anxiety is significant or persistent, that's a reason to talk to a clinician, who can address both the physical and psychological pieces.

The psychology of changing your relationship with food

Evidence tier: 2 — recognized but under-discussed.

This is the part that gets too little attention. GLP-1 drugs don't just change a number on the scale — they change how you experience hunger, fullness, reward, and eating, and that psychological shift is significant. Many people describe the quieting of "food noise" as liberating. But others find that food had been carrying emotional weight — comfort after a hard day, celebration, connection, routine — and when the drive to eat drops away, they have to find other ways to meet those needs. That adjustment can bring a period of low mood, boredom, or a sense of loss, even amid successful weight loss.

Understanding this reframes a lot of the "GLP-1 made me feel off" reports: they may reflect a genuine psychological transition rather than a chemical mood effect. The constructive response is to expect the adjustment and build support around it — other coping strategies, social connection, and, where useful, talking to a therapist or a clinician who understands the emotional side of weight change. Treating the psychological dimension as real and worth tending, rather than dismissing it, is part of using these drugs well. It's also why medical supervision — rather than a self-directed gray-market approach — helps: a clinician can watch the whole picture, not just the weight.

When should you seek help?

Evidence tier: 2 — safety guidance.

Regardless of what any drug does or doesn't cause, your mental health is worth acting on. Reach out to a clinician if you notice new or worsening depression, persistent low mood, loss of interest, significant anxiety, or any thoughts of harming yourself while on a GLP-1 (or at any time). This isn't about assuming the drug is to blame — it's that these symptoms deserve attention and support on their own terms, and a clinician can help sort out causes and options, including whether to adjust or stop the medication. If you have a history of depression, anxiety, or an eating disorder, flag it before starting so your care can be tailored.

The overall message is balanced: the frightening suicidality claim did not survive systematic review, and there's no good evidence these drugs cause depression — but mood, anxiety, and the psychology of changed eating are real experiences that some people navigate, and they warrant monitoring and support rather than silence. Don't let a reassuring evidence base talk you out of getting help if you're struggling.

Limitations

This is educational content, not medical advice.

• The evidence on suicidality is reassuring — FDA and EMA found no causal link; the warning was removed.
• No strong evidence GLP-1s cause depression — but individual mood experiences vary.
• Anxiety and low-mood reports are real but not established as direct drug effects; often tied to GI symptoms or the eating-relationship shift.
• History of depression, anxiety, or eating disorders warrants discussion with your prescriber before starting.
• Seek help for any new or worsening mental-health symptoms — regardless of cause.
• Marko Maal, MSc Pharmacy reviewed this article. Reviewer attribution does not constitute a doctor-patient relationship.

The bottom line

The scariest claim about GLP-1 drugs and mental health — that they cause suicidal thoughts — did not hold up: after thorough review, the FDA found no increased risk and had the warning removed, European regulators found no causal link, and a large study associated semaglutide with lower suicidal-ideation risk. There's also no strong evidence these drugs cause depression. What's real is that mood, anxiety, and the psychology of a suddenly-changed relationship with food are experiences some people navigate on these drugs, and they deserve monitoring and support rather than dismissal. Use the medication under medical supervision, tell your clinician about any mental-health history, and reach out for help if your mood or anxiety worsens — the reassuring evidence base is no reason to struggle alone.

This article touches on mental health and suicidal thoughts. If you're experiencing thoughts of self-harm or a mental-health crisis, please reach out to a mental-health professional or a crisis line in your country — support is available, and you don't have to face it alone.

Related on this site

• Managing GLP-1 side effects
• GLP-1 complete guide
• GLP-1s, gallbladder & pancreatitis: the risks
• Selank for anxiety: the evidence
• Our evidence-tier framework

References

• U.S. Food and Drug Administration. FDA requests removal of suicidal behavior and ideation warning from GLP-1 receptor agonist medications. FDA.gov — no increased suicidality risk; warning removed.
• European Medicines Agency, PRAC. 2024. Review of GLP-1 receptor agonists and suicidal thoughts/self-harm — no causal relationship. EMA — EU regulatory conclusion.
• Wang W, et al. 2024. Association of semaglutide with risk of suicidal ideation in a real-world cohort. Nat Med. PMID 38182782 — lower suicidal-ideation risk vs comparators.